Monographie - Pentamidine isetionate

Letztes “update” :
08/05/2024

Pentamidine isetionate

Chemische Struktur

Handelsmarke

Handelsnamen sind als beispielhaft anzusehen. Sonstige Bestandteile können je nach Hersteller oder Land verschieden sein

DBL Pentamidine isetionate	Malaysia
Manicare	Argentinien
Nebupent	Vereinigte Staaten von Amerika
Pentacarinat	Belgien, Dänemark, Deutschland, Finnland, Frankreich, Griechenland, Großbritannien, Italien, Kolumbien, Luxemburg, Neuseeland, Niederlande, Österreich, Schweden, Schweiz, Spanien
Pentam	Vereinigte Staaten von Amerika
Pentamidina	Argentinien, Spanien
Pentamidine isethionate	Australien, Kanada, Malaysia, Vereinigte Staaten von Amerika
Pentamina	Portugal

Literaturverzeichnis : Pentamidine isetionate

	Typ	Veröffentlichung
36	Zeitung	Alex S, Gupta SL, Minor JR, Turcovski-Corrales S, Gallelli JF, Taub D, Piscitelli SC. Compatibility and activity of aldesleukin (recombinant interleukin-2) in presence of selected drugs during simulated Y-site administration: Evaluation of three methods. Am J Health-Syst Pharm 1995 ; 52: 2423-2426.
73	Zeitung	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
198	Zeitung	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
275	Zeitung	Lewis JD, El-Gendy A. Cephalosporin-pentamidine isethionate incompatibilities. Am J Health-Syst Pharm 1996 ; 53: 1461-1462.
337	Zeitung	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
424	Zeitung	De NC, Alam AS, Kapoor JN. Stability of pentamidine isethionate in 5% dextrose and 0.9% sodium chloride injections. Am J Hosp Pharm 1986 ; 43: 1486-1488.
496	Zeitung	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
604	Labor	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
1135	Zeitung	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1235	Zeitung	Leigh PH, Buddle GC. Pentamidine infusion stability. Br J Pharm Pract 1988 ; 10: 22-23.
1625	Zeitung	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1925	Zeitung	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
3543	Labor	Ceftazidime – Summary of Product Characteristics Wockhardt 2013
3559	Labor	Pentamidine diiséthionate (Pentacarinat®) - Résumé des caractéristiques du produit Sanofi Aventis France 2013
3560	Labor	Linezolid (Zyvox®) - Summary of Product Characteristics Pharmacia 2013
3662	Labor	Foscavir (Foscarnet®) - Summary of Product Characteristics Clinigen 2014

Mentions Légales